SG11201407533SA - Antiviral compounds - Google Patents

Antiviral compounds

Info

Publication number
SG11201407533SA
SG11201407533SA SG11201407533SA SG11201407533SA SG11201407533SA SG 11201407533S A SG11201407533S A SG 11201407533SA SG 11201407533S A SG11201407533S A SG 11201407533SA SG 11201407533S A SG11201407533S A SG 11201407533SA SG 11201407533S A SG11201407533S A SG 11201407533SA
Authority
SG
Singapore
Prior art keywords
international
california
foster city
compounds
gilead sciences
Prior art date
Application number
SG11201407533SA
Other languages
English (en)
Inventor
John O Link
Jeromy J Cottell
Martin Teresa Alejandra Trejo
Elizabeth M Bacon
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG11201407533SA publication Critical patent/SG11201407533SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201407533SA 2012-05-16 2013-05-15 Antiviral compounds SG11201407533SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647966P 2012-05-16 2012-05-16
US13/831,116 US20130309196A1 (en) 2012-05-16 2013-03-14 Antiviral compounds
PCT/US2013/041201 WO2013173488A1 (en) 2012-05-16 2013-05-15 Antiviral compounds inhibitors of hcv ns5b

Publications (1)

Publication Number Publication Date
SG11201407533SA true SG11201407533SA (en) 2014-12-30

Family

ID=49581469

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201407533SA SG11201407533SA (en) 2012-05-16 2013-05-15 Antiviral compounds
SG10201703451RA SG10201703451RA (en) 2012-05-16 2013-05-15 Antiviral compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201703451RA SG10201703451RA (en) 2012-05-16 2013-05-15 Antiviral compounds

Country Status (19)

Country Link
US (5) US20130309196A1 (cs)
EP (2) EP3239153B1 (cs)
JP (2) JP6209209B2 (cs)
KR (2) KR102078233B1 (cs)
CN (3) CN106432254B (cs)
AU (3) AU2013262874B2 (cs)
BR (1) BR112014028221B1 (cs)
CA (1) CA2873485C (cs)
EA (2) EA034749B1 (cs)
ES (2) ES2628350T3 (cs)
HK (1) HK1245262B (cs)
IL (1) IL235645A0 (cs)
IN (1) IN2014MN02459A (cs)
MX (1) MX362060B (cs)
PL (2) PL2850085T3 (cs)
PT (2) PT2850085T (cs)
SG (2) SG11201407533SA (cs)
SI (2) SI2850085T1 (cs)
WO (1) WO2013173488A1 (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734052A1 (en) 2003-05-30 2005-01-13 Pharmasset, Inc. Modified fluorinated nucleoside analogues
CA2817840A1 (en) 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds
KR102241651B1 (ko) 2011-11-16 2021-04-20 길리애드 파마셋 엘엘씨 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SI3650014T1 (sl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
US20150064252A1 (en) * 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TWI679203B (zh) 2014-06-11 2019-12-11 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
CN106715446B (zh) * 2014-07-02 2019-11-08 路易斯安那泽维尔大学 使含至少一个酚基(或芳羟基)的药物分子提高生物利用度和降低剂量要求的硼基前药策略
EP3939985B1 (en) 2014-12-26 2024-05-08 Emory University Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections
EP3426245B1 (en) 2016-03-07 2022-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
ES2926579T3 (es) * 2016-05-05 2022-10-27 Laurus Labs Ltd Proceso para la preparación de compuestos intermedios útiles en la preparación de inhibidores del virus de la Hepatitis C (VHC)
CN118178652A (zh) 2016-05-27 2024-06-14 吉利德科学公司 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
CN108368123B (zh) * 2016-07-08 2021-02-19 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
CN106220639A (zh) * 2016-07-22 2016-12-14 上海众强药业有限公司 一种维帕他韦中间体新晶型
CN107573380B (zh) * 2016-11-30 2020-06-02 上海博志研新药物技术有限公司 维帕他韦中间体、制备方法及应用
CA3073986A1 (en) 2017-08-28 2019-03-07 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
BR122022008466B1 (pt) 2017-12-07 2023-12-05 Emory University Uso de um composto
JP7536761B2 (ja) 2018-11-21 2024-08-20 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
EP4199925A4 (en) * 2020-08-18 2024-08-28 Merck Sharp & Dohme LLC CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
US12037340B2 (en) * 2021-05-21 2024-07-16 Gilead Sciences, Inc. Pentacyclic derivatives as Zika virus inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO2003007945A1 (en) * 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
DK1778702T3 (da) 2004-07-16 2011-10-17 Gilead Sciences Inc Antivirale forbindelser
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0822335A2 (pt) 2008-02-12 2019-09-24 Bristol-Myers Squibb Company inibidores do vírus da hepatite c
CA2715839C (en) 2008-02-13 2014-12-09 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010062821A1 (en) 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
KR20110098779A (ko) 2008-12-03 2011-09-01 프레시디오 파마슈티칼스, 인코포레이티드 Ｈｃｖ ｎｓ5ａ의 억제제
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
SG174146A1 (en) 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
CA2755658A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
US9139569B2 (en) 2009-05-12 2015-09-22 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
PT3002281T (pt) * 2009-05-13 2017-11-14 Gilead Pharmasset Llc Compostos antivirais
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011028596A1 (en) 2009-09-04 2011-03-10 Glaxosmithkline Llc Chemical compounds
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20120276047A1 (en) 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
KR20130008040A (ko) 2010-03-09 2013-01-21 머크 샤프 앤드 돔 코포레이션 융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2800530A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
EP2963034A1 (en) 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
WO2012050918A2 (en) * 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
CA2817840A1 (en) * 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
KR102241651B1 (ko) * 2011-11-16 2021-04-20 길리애드 파마셋 엘엘씨 항바이러스성 화합물로서의 축합된 이미다졸릴이미다졸
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
CN104487442A (zh) 2015-04-01
SI2850085T1 (sl) 2017-08-31
US20190337960A1 (en) 2019-11-07
PL3239153T3 (pl) 2019-09-30
SG10201703451RA (en) 2017-06-29
PT3239153T (pt) 2019-07-30
EP2850085A1 (en) 2015-03-25
US20130309196A1 (en) 2013-11-21
CN106432254A (zh) 2017-02-22
KR20200017557A (ko) 2020-02-18
JP6408656B2 (ja) 2018-10-17
CN109970749A (zh) 2019-07-05
EP3239153B1 (en) 2019-05-08
KR20150008908A (ko) 2015-01-23
HK1245262B (en) 2020-01-10
US10800789B2 (en) 2020-10-13
HK1205126A1 (en) 2015-12-11
AU2013262874A1 (en) 2014-12-11
JP2015517527A (ja) 2015-06-22
PL2850085T3 (pl) 2017-10-31
BR112014028221A2 (pt) 2020-10-27
IN2014MN02459A (cs) 2015-07-10
CA2873485C (en) 2020-05-05
KR102078233B1 (ko) 2020-02-17
IL235645A0 (en) 2015-02-01
EA201790963A1 (ru) 2018-02-28
AU2019204423A1 (en) 2019-07-11
WO2013173488A1 (en) 2013-11-21
ES2628350T3 (es) 2017-08-02
AU2013262874A2 (en) 2015-01-22
AU2017248566A1 (en) 2017-11-09
JP6209209B2 (ja) 2017-10-04
JP2017160276A (ja) 2017-09-14
EP3239153A1 (en) 2017-11-01
BR112014028221B1 (pt) 2022-05-03
EA028026B1 (ru) 2017-09-29
AU2013262874B2 (en) 2017-11-02
MX2014013660A (es) 2015-04-17
US20160115175A1 (en) 2016-04-28
CN104487442B (zh) 2016-10-26
MX362060B (es) 2019-01-07
US20140316144A1 (en) 2014-10-23
SI3239153T1 (sl) 2019-08-30
US20170342085A1 (en) 2017-11-30
US9682989B2 (en) 2017-06-20
EP2850085B1 (en) 2017-03-15
EA034749B1 (ru) 2020-03-17
ES2738012T3 (es) 2020-01-17
EA201492002A1 (ru) 2015-11-30
CN106432254B (zh) 2018-12-28
PT2850085T (pt) 2017-06-26
CA2873485A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
SG11201407533SA (en) Antiviral compounds
SG11201408047XA (en) Macrocyclic inhibitors of flaviviridae viruses
SG11201408013WA (en) Solid forms of an antiviral compound
SG11201407115XA (en) Carboxylic acid compounds
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201804294WA (en) Tank-binding kinase inhibitor compounds
SG11201408739VA (en) Inhibitors of hepatitis c virus
SG11201408011SA (en) Synthesis of antiviral compound
SG11201907058TA (en) Hiv inhibitor compounds
SG11201408094YA (en) Neprilysin inhibitors
SG11201408064PA (en) Macrocyclic inhibitors of flaviviridae viruses
SG11201408539UA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201408261UA (en) Syringe
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201408045UA (en) MACROCYCLIC INHIBITORS OF <i>FLAVIVIRIDAE</i> VIRUSES
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201408769QA (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201804674UA (en) Heteroarylhydroxypyrimidinones as agonists of the apj receptor
SG11201811416VA (en) Crystalline solid forms of a bet inhibitor
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors